Regarding "Avigan", which has been applied for approval as a therapeutic drug for the new coronavirus, as a result of the clinical trial, Fujifilm could not confirm the effect of suppressing the severity of the disease. announced that it would withdraw its application.
"Avigan" is a drug developed by FUJIFILM Toyama Chemical Co., Ltd. for the treatment of new strains of influenza, and it has been applied for approval as it is expected to be effective against the new coronavirus. It was a continuous deliberation.
Since April last year, the company has been conducting clinical trials under a new framework for mild corona patients aged 20 and over who are at risk of becoming severe. No significant results were obtained by suppressing .
In response to this result, the company announced that it would discontinue development as a treatment for the new corona and withdraw the application for approval.
At the beginning of the spread of the new corona infection, the government aimed for early approval of Avigan as a therapeutic drug, and was also stockpiling it for the new corona.
Fujifilm said, ``At the beginning of the spread of the infection, there were no candidates for the treatment of the new coronavirus, and development proceeded by diverting existing drugs, but we believe that the pathology has been elucidated and the role has ended.Thank you for your cooperation in the clinical trial. I would like to thank all the patients and healthcare workers who have been affected."